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hospitalization claims was searched from January 1, 1995
to December 31, 2000 to identify patients. Healthcare uti-
lization and associated costs were studied one year prior
to the start of salmeterol therapy and one year after. Log
transformations were done to normalize the data. Paired
t-tests were performed to assess differences in asthma-
related healthcare utilization and costs in the pre and
post-salmeterol periods. RESULTS: Short-acting b2-
agonist utilization increased from an average of 7.63
claims (SD = 7.45) in the pre-salmeterol period to an
average of 8.39 claims (SD = 6.73) in the post-salmeterol
period (t = -2.34, p = .022) and the costs increased from
an average of $217.56 (SD = 264.13) in the pre-salme-
terol period to an average of $219.31 (SD = 231.65) in
the post-salmeterol period (t = -2.30, p = .024). Inhaled
steroid use increased signiﬁcantly from an average of 3.36
claims (SD = 4.55) in the pre-salmeterol period to an
average of 6.29 claims (SD = 4.26) in the post-salmeterol
period (t = -7.87, p = .00) and the costs also increased
from an average of $149.82 (SD = 234.10) in the pre-sal-
meterol period to an average of $313.50 (SD = 269.74)
in the post-salmeterol period (t = -7.40, p = .00). Total
medication costs increased from $559.74 (SD = 655.08)
in the pre-salmeterol period to $1155.51 (SD = 604.70)
in the post- salmeterol period (t = -8.27, p < 0.001). Total
healthcare costs also increased signiﬁcantly from $1356
to $2090 in the post-salmeterol period (t = -6.89, p <
0.001. CONCLUSIONS: The introduction of salmeterol
increased overall asthma-related healthcare utilization
and costs but this may have been due to increasing asthma
severity in this population as indicated by the increased
utilization of short-acting b2-agonist and inhaled steroids.
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OBJECTIVE: Recent studies demonstrate the cost-
effectiveness of inhaled corticosteroids (ICS) in adults.
However, they fail to account for the impact of ICS-
induced bone mineral density (BMD) loss and resultant
hip fractures. METHODS: We used a previously pub-
lished Markov model to compare quick relievers (e.g., 
b-agonists) alone vs. the addition of ICS therapy. State-
space dimensions included patient age, clinical history,
and lung function (FEV1% predicted). Risk functions
were estimated using symptom, exacerbation, and hospi-
talization rates obtained from literature reviews and
analyses of primary, cross-sectional data. Societal costs
were derived from published economic studies of inpa-
tient and outpatient asthma. We used published data
retrieved from 3 RCTs and 3 qualiﬁed observational
studies to estimate yearly change in hip BMD ranging
from 0.000933g/cm2 to -0.00058g/cm2 per 100mcg stan-
dard ICS dosage. ICS side-effects were modeled as an
annual reduction in age-predicted BMD. Risk functions
to link BMD to hip fracture rates and QOL weights for
hip fracture were derived from published estimates.
RESULTS: In the absence of BMD decline, we estimated
an incremental cost-effectiveness ratio of $15,000 per
quality-adjusted life-year (QALY) for ICS therapy. In sen-
sitivity analysis, we considered 3 alternative BMD decline
scenarios (none; mean; high) and 4 alternative models of
the temporal impact of ICS on BMD (10-, 20-, 30-year,
and lifetime). Incremental cost-effectiveness ratios under
various combinations of these two variables ranged from
$15,000 to over $130,000/QALY. The ICS therapy strat-
egy was dominated (i.e., it produced both higher costs
and lower total QALYs) under the “high” BMD decline
scenario with temporal risk greater than “30-years.”
CONCLUSION: The economic attractiveness of inhaled
steroids is highly dependent upon what is assumed about
their impact on BMD and the resultant fracture rate.
More research is needed on these variables before deﬁn-
itive cost-effectiveness conclusions can be drawn.
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OBJECTIVES: We studied the cost implications of
putting moderate or severe adult asthma patients on 
combined long-term-control drug therapy (inhaled corti-
costeroids + long-term-control bronchodilators) versus on
inhaled corticosteroids alone. METHODS: The study
sample was retrospectively selected from Medi-Cal eligi-
bles between January 1995 and December 2000. The ﬁnal
data set included 1547 patients. The targeted asthma
patient population was moderate and severe adult asthma
patients who recently had an asthma-related urgent event
(asthma related hospitalization or emergency care). One-
year total healthcare cost was compared between the
combined therapy and the monotherapy. Both the average
treatment effect (ATE) and the treatment effect on the
treated (TT) were estimated. A linear outcome-equation
model and a propensity score method were applied to
adjust for observed selectivity, and a parametric switch-
ing regression model for both observed and unobserved
selection bias. Sociodemographic variables, comorbidi-
ties, previous healthcare cost, key-event type, and drug
utilization were adjusted. All costs were adjusted to 1999
U.S. dollars using the medical care CPI. RESULTS: When
adjusting only the observed selectivity using either the
linear outcome-equation model or the propensity score
method, we found no statistical signiﬁcant difference in
one-year total health care costs between the combined
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therapy and the monotherapy. However, when the unob-
served selectivity was also adjusted using the switching
regression model, the combined therapy was less expen-
sive (at 90% CI) in both the treated population (TT) and
the general population (ATE). The TT was even less than
ATE and the marginal savings would be $3150 annually.
CONCLUSIONS: Given the combined therapy’s clinical
beneﬁt shown in previous studies, it is the dominant long-
term asthma-control therapy in the studied population.
The difference in ATE and TT indicates that the combined
therapy was given to patients whose health status could
be improved the most by it.
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OBJECTIVES: To assess the utilization and costs for
medical resources and pharmacotherapy among patients
with asthma in a state Medicaid population. METHODS:
Outpatient, hospital and emergency department (ED)
claims with a primary ICD-9 code for asthma (493.XX)
dated between January 1 through December 31, 1999
were extracted from a state Medicaid claims database.
Unique recipient identiﬁers obtained from these claims
were then used to extract asthma-related prescription
claims. Medicaid reimbursements were used to calculate
costs for outpatient, ED and prescription drug use, and
1999 Medicare DRG reimbursement amounts provided
by the Centers for Medicare and Medicaid Services
(CMS) were used to calculate hospital costs. Based on the
pharmacotherapy received, recipients were classiﬁed into
one of four categories: 1) short-acting beta-agonist use
only; 2) use of combination therapy without inhaled anti-
inﬂammatory medications; 3) use of any inhaled anti-
inﬂammatory therapy (inhaled corticosteroids, cromolyn,
or nedocromil); or 4) no prescription claims for asthma-
related medications. RESULTS: Overall asthma preva-
lence was 17.7/1000 Medicaid recipients. Of the 6051
recipients identiﬁed with asthma, 20.4% (n = 1233)
received short-acting beta-agonist therapy only, 34.8% 
(n = 2108) received combination therapy without 
inhaled anti-inﬂammatory drugs, 35.9% (n = 2170)
received at least one inhaled anti-inﬂammatory drug, and
8.9% (n = 540) had no prescription claims for asthma-
related medications. The hospitalization rate was 21 hos-
pitalizations/10,000 recipients at a mean cost of $3737
(SD = $1322) per visit per recipient (pvpr). The rates of
outpatient and ED use were 21 outpatient visits/1000
recipients, and 69 ED visits/10,000 recipients. The mean
cost pvpr for outpatient and ED use was $54 (SD = $72)
and $101 (SD = $126), respectively. The total asthma-
related expenditures to Medicaid were: $2,690,777 
for hospitalizations; $236,857 for ED use; $589,878 for 
outpatient use; and $1,813,240 for prescription use. 
CONCLUSIONS: Asthma is responsible for a substantial
economic burden to Medicaid, with hospital use account-
ing for most of the dollars.
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OBJECTIVES: Asthma patients’ lack of adherence to
inhaled corticosteroids (IC) contributes to treatment
failure and over $6.2 billion in associated costs. In disease
states such as hypertension, adherence rates ≥80% are
related to clinical success. Similar adherence rates for IC
in asthma patients have not yet been determined. This
study was designed to assess the relationship between IC
adherence rate and Total Medical and Drug Costs
(TMDC). METHODS: Data were from a commercial,
integrated pharmacy/medical claims database. Patients
ranging from 4 to 55 years with at least 2 claims for an
IC, a 120-day beneﬁt history, and a 360-day continuous
enrollment were included. Patients were excluded if they
were also coded for non-asthma-related pulmonary dis-
eases. Age, gender, and concomitant drug/disease infor-
mation were collected. The adherence rate was deﬁned as
[Total days supply of IC/(last RX date less ﬁrst RX date
+ last days supply)]. TMDC included drug, hospital,
physician visit and lab costs. The number of Disease
Related Events (DRE) was also determined. ANOVA or
equivalent tests, along with multiple regression tech-
niques were used to test hypotheses. RESULTS: Six
hundred forty-three patients were identiﬁed. The mean
age was 30.5 ± 15.8, with 43.5% males. We classiﬁed
8.5% of patients as 80–99% adherent, 8.2% between
60–79% adherent, 14.9% between 40–59% adherent,
and 70.6% of patients were 39% adherent. There was no
signiﬁcant difference in the TMDC among adherence
quintiles. The regression demonstrated a statistically sig-
niﬁcant correlation (r = 0.76) between age (p < 0.0001),
number of medications (p < 0.0001), co-morbidities 
(p < 0.0001), use of budesonide inhaler (p = 0.0081) or
long-acting beta agonists (p = 0.0017) against the log 
of TMDC. There were no items inversely correlated to
TMDC. There was no difference in DRE between patients
<80% or ≥80% adherent. (c2 = 0.3511, 1 d.f., p =
0.5535). CONCLUSION: Based on this study, there was
not signiﬁcant linear correlation between adherence to IC
and TMDC.
